Tesamorelin — Visceral Fat
tesamorelin is the GHRH analog with the strongest clinical data for reducing visceral fat — a daily bedtime protocol built around one key timing insight.
Why this protocol
tesamorelin is a GHRH analog: it prompts the pituitary to release growth hormone, and in its pivotal Phase III trials that translated into a meaningful reduction in visceral (deep abdominal) fat with a rise in IGF-1. It is the GH peptide with the most direct human evidence for body composition.
The protocol lives and dies on timing. GH release is blunted by both insulin (high after meals) and somatostatin, so the dose is taken at bedtime, ~2–3 hours after the last meal, to land in the body's natural overnight GH window.
The 2 mg dose is the approved/trial dose (for HIV-associated lipodystrophy); using it for general body composition is off-label extrapolation, framed here as convention. Doses match the Tesamorelin page. No therapeutic claims.
The regimen
Tesamorelin
GHRH / visceral fat- Dose
- 2 mg (conservative start 1 mg)
- Schedule
- Once daily · subcutaneous
- Timing
- Bedtime, ~2–3 h after the last meal
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
28
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.28 mL
- Doses per vial
- 7
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 7 days
- Every other day
- 14 days
- 5×/week
- 10 days
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
Cycle & schedule
Cycle (8–16 weeks)
Tesamorelin 2 mg once daily at bedtime on a relatively empty stomach (some start at 1 mg for body-composition goals). The Phase III visceral-fat effect builds over the full cycle.
Washout (4–8 weeks)
Take 4–8 weeks off; check IGF-1 and fasting glucose during the break before deciding whether to repeat.
Studies behind this protocol
This protocol composes the cited evidence on each peptide's page — see the full bibliography on: Tesamorelin.
Research use only · Not medical advice · Updated 2026-06-01